Developed a Brain Tumor? Get the Justice You Deserve

Legal experts project compensation ranges based on case severity:

• High-Value Cases: $500,000 - $1,000,000+ (Grade II/III tumors, multiple surgeries, permanent damage)
• Mid-Tier Cases: $200,000 - $500,000 (Grade I tumors requiring surgery, significant complications)
• Conservative Cases: $150,000 - $300,000 (minimal treatment required, no permanent damage)

For comparison: Bayer paid $2.04 billion for 10,300 Yaz blood clot claims (avg. $198K) and $1.6 billion for 39,000 Essure claims. Given brain tumor severity and Pfizer's $150+ billion company value, Depo-Provera settlements could be substantial.

Nothing upfront. We work on a contingency fee basis, which means:

• No attorney fees unless we win your case
• No out-of-pocket expenses for investigation or filing
• We cover all case costs during litigation
• Our fee is a percentage of your settlement (typically 33-40%)

Timeline varies, but Judge Rodgers is known for moving cases quickly:

• Case Development: 2-6 months (initial filing and documentation)
• MDL Discovery: 6-18 months (evidence gathering phase)
• Settlement/Trial: Late 2026 - Early 2027 (bellwether trials expected)

Judge M. Casey Rodgers, who oversaw the $6 billion 3M earplug settlement, is aggressively pushing these cases. Settlement negotiations could begin much sooner than typical pharmaceutical litigation due to the rapid case growth (25% monthly) and strong scientific evidence.

The MDL requires specific documentation:

• Medical: Brain tumor diagnosis, pathology reports, surgical records, MRI/CT imaging studies
• Usage: Medical records confirming Depo-Provera injections (at least 2 injections), pharmacy records
• Timeline: Proof that meningioma diagnosis occurred after Depo-Provera use began
• Questionnaire: Completed "Plaintiff Proof of Use/Injury Questionnaire" within 120 days

Don't worry if you're missing documents - our legal team can help obtain necessary medical records through court-authorized discovery processes.

Yes, time limits apply and vary by state. Generally:

• Personal injury: 2-3 years from brain tumor diagnosis or discovery
• Wrongful death: 2-3 years from death
• Discovery rule: Clock may start when connection to Depo-Provera is discovered

Critical: With bellwether trials approaching in 2025, now is the time to file. Contact us immediately to ensure you don't miss your deadline.

You may qualify if you have:

• Qualifying diagnosis: Meningioma (brain tumor), intracranial tumor requiring surgery, or other brain-related complications
• Depo-Provera use: Received at least two injections of Depo-Provera or Depo-SubQ for contraception or medical treatment
• Timeline: Brain tumor diagnosis occurred after starting Depo-Provera treatment

Family members can also file wrongful death claims for deceased relatives who meet these criteria.

Depo-Provera litigation is rapidly progressing:

• Over 435 active lawsuits in MDL 3140 (Northern District of Florida) under Judge M. Casey Rodgers
• Key dates: September 29, 2025 hearing on Pfizer's federal preemption motion
• Discovery deadlines: July 25, 2025 for preemption issues; September 23, 2025 for general causation
• Explosive growth: From 78 cases in March to 435+ by July 2025
• Scientific basis: 2024 BMJ study showing 5.6x increased meningioma risk

With international warning labels already in place in EU/UK/Canada, pressure is mounting for U.S. settlements before bellwether trials.

The Depo-Provera litigation has several powerful advantages:

• Failure to Warn: Pfizer provides meningioma warnings in EU/UK/Canada but not the U.S.
• Long-term Knowledge: Scientific literature from 1983 established the progesterone-meningioma link
• Design Defect: Pfizer's own lower-dose Depo-SubQ provides same efficacy with potentially less risk
• Corporate Admissions: Pfizer acknowledged the connection to The Guardian in March 2024
• FDA Database: 46 reported meningioma cases linked to the drug since 2000

This creates compelling evidence of a conscious decision to withhold critical safety information from American women while warning women in other countries.